Page last updated: 2024-11-03

prazosin and Chronic Disease

prazosin has been researched along with Chronic Disease in 86 studies

Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.

Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

Research Excerpts

ExcerptRelevanceReference
"To explore the efficacy of levofloxacin, terazosin, and their combination in patients with category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)."9.22A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. ( Liang, K; Wang, J; Xu, Z; Yan, D, 2016)
"To investigate the efficacy and safety of the alpha1-receptor inhibitor terazosin combined with chlormezanone in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)."9.14[Retrospective analysis of the combined therapy of terazosin with chlormezanone for chronic prostatitis/chronic pelvic pain syndrome]. ( Li, HJ; Li, HZ; Yan, S; Zhang, XY, 2009)
"To evaluate the clinical efficacy and safety of dexketoprofen trometamol in the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)."9.14[Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome]. ( Jiang, MH; Liu, HL; Wu, GC, 2009)
"To evaluate the initial, long-term, and durable response rates to terazosin, placebo, or other therapies in patients with chronic prostatitis/chronic pelvic pain syndrome."9.11Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2004)
"Terazosin proved superior to placebo for patients with chronic prostatitis/chronic pelvic pain syndrome who had not received alpha-blockers previously."9.10Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2003)
"Right heart catheterization was performed before and during long-term therapy with prazosin in 27 patients with severe chronic heart failure who underwent serial hemodynamic studies during 3 to 12 weeks of treatment with the drug."9.06Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1986)
"The effects of prazosin therapy were recently evaluated in ambulatory patients with essential hypertension and chronic obstructive pulmonary disease."9.06Prazosin in hypertensive patients with chronic bronchitis and asthma: a brief report. ( Chodosh, S; Pizzuto, D; Tuck, J, 1989)
"The long-term effects of prazosin in chronic congestive heart failure were studied in 10 patients (New York Heart Association class III-IV) in a double-blind cross-over study."9.06Hemodynamic effects at rest and during exercise in long-term treatment with prazosin in chronic congestive heart failure. ( Koss, A; Sivertssen, E; Westheim, A, 1986)
"Ten patients with severe chronic heart failure were given prazosin 5 mg and captopril 25 mg in random order on consecutive days."9.05Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects. ( Coxon, R; Sharpe, DN, 1982)
"Long-term treatment of congestive heart failure with prazosin is disputed."9.05[Lack of symptomatic and long-term hemodynamic effects of prazosin in chronic heart failure. Double-blind, randomized study over one year]. ( Bussmann, WD; Kaltenbach, M; Nadj, M; Reifart, N; Schmidt-Moritz, AD, 1985)
"The acute haemodynamic effects of prazosin 5 mg were investigated in 11 patients with severe chronic congestive cardiac failure."9.05Prazosin in the treatment of severe chronic congestive cardiac failure. ( Clarke, GM; Cope, GD; Hockings, BE; Taylor, RR, 1980)
"To investigate the mechanism of pharmacodynamic tolerance reported to occur during prazosin therapy of chronic congestive heart failure, we measured plasma norepinephrine, plasma epinephrine, plasma renin activity (PRA) and plasma aldosterone, as well as hemodynamics in eight patients with chronic congestive heart failure, functional class III and IV (NYHA), before and during 10 weeks of prazosin therapy."9.05Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure. ( Henry, DP; Stein, L; Weinberger, MH, 1981)
" In cobalt-induced epilepsy in the rat activity is associated with a cortical NA denervation."8.77Chronic cobalt-induced epilepsy: noradrenaline ionophoresis and adrenoceptor binding studies in the rat cerebral cortex. ( Bregman, B; Chauvel, P; Le Saux, F; Maurin, Y; Trottier, S, 1985)
"Oral prazosin hydrochloride (2-20 mg/day) was administered to 38 patients with chronic congestive heart failure due to ischemic heart disease for 6-18 months."7.68Prazosin in chronic congestive heart failure due to ischemic heart disease. ( Antani, JA; Antani, NJ; Nanivadekar, AS, 1991)
"The effect of vasodilator therapy in chronic obstructive lung disease with pulmonary hypertension was evaluated in eight patients during oral prazosin therapy (2-10 mg day-1)."7.67Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale. ( Halvorsen, FJ; Jentoft, H; Vik-Mo, H; Walde, N, 1985)
"The comparative haemodynamic effects of oral prazosin hydrochloride and hydralazine were evaluated in 11 patients with chronic congestive heart failure."7.66Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure. ( Arnold, S; Brundage, B; Chatterjee, K; Parmley, W; Ports, TA, 1979)
"The persistence of the hemodynamic effects of prazosin was studied in 12 patients with chronic congestive heart failure."7.66Attenuation of prazosin effect on cardiac output in chronic heart failure. ( Arnold, SB; Baughman, RA; Benet, LZ; Chatterjee, K; Parmley, WW; Ports, TA; Williams, RL, 1979)
"The haemodynamic effects of oral prazosin and hydralazine were evaluated in patients with refractory heart failure and compared with those of intravenous nitroprusside in the same patients."7.66Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure. ( Conti, CR; Iacona, M; Mehta, J; Pepine, CJ, 1979)
"The acute hemodynamic effects of oral prazosin were investigated in 7 patients with chronic refractory heart failure."7.66Acute and chronic cardiocirculatory effects of oral prazosin in chronic refractory heart failure. ( Fukaya, T; Hayashi, H; Matsui, E; Niwa, T; Oba, M; Okubo, M; Sassa, H, 1980)
"In addition to digitalis and diuretics, 10 patients with chronic cardiac failure were treated with prazosin (15 mg/d) over a period of 6 months."7.66[Prazosin long-term treatment in severe chronic cardiac failure (author's transl)]. ( Bleifeld, W; Hanrath, P; Kuck, KH; Mathey, D; Zehnke, A, 1980)
"Twelve patients with severe chronic congestive heart failure (CHF) (NYHA class III and IV) resistant to digitalis and diuretics were treated with the postsynaptic alpha-blocking agent prazosin (PZ) (3 to 20 mg/day)."7.66Sustained effectiveness of chronic prazosin therapy in severe chronic congestive heart failure. ( Bertel, O; Bühler, FR; Burkart, F, 1981)
"To evaluate whether long-term administration of the oral vasodilator, prazosin, in the ambulatory therapy of chronic refractory congestive heart failure (CHF) results in gradual attentuation of its marked salutary peripheral circulatory relaxing actions, 16 coronary heart failure patients receiving chronic prazosin, 16 mg daily, were assessed for the development of vasodilator tolerance for 12 months."7.66Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy. ( Awan, NA; DeMaria, AN; Lee, G; Mason, DT, 1981)
"The long-term efficacy of the new oral vasodilator, prazosin (PZ), was evaluated in nine patients with refractory heart failure due to chronic coronary heart disease."7.65Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodyn ( Awan, NA; DeMaria, AN; Mason, DT; Maxwell, KS; Miller, RR; Neumann, A, 1977)
"Terazosine was effective for the treatment of CPPS."6.70Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. ( Eroğlu, M; Gül, O; Ozok, U, 2001)
"Prudence is indicated in patients with congestive heart failure due to coronary artery disease."5.27A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983)
"To explore the efficacy of levofloxacin, terazosin, and their combination in patients with category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)."5.22A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. ( Liang, K; Wang, J; Xu, Z; Yan, D, 2016)
"We obtained NIH-CPSI and IIEF-5 scores from 132 chronic prostatitis patients with ED and divided the patients into a control (n = 70) and a treatment group (n = 62), the former treated with oral levofloxacin 0."5.16[Efficacy of compound Xuanju capsule in the treatment of chronic prostatitis with erectile dysfunction]. ( Chao, WF; Huang, XK; Liang, P; Liu, JW; Wang, L; Wang, QT; Yang, H; Yang, W; Zhou, P, 2012)
"To investigate the efficacy and safety of the alpha1-receptor inhibitor terazosin combined with chlormezanone in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)."5.14[Retrospective analysis of the combined therapy of terazosin with chlormezanone for chronic prostatitis/chronic pelvic pain syndrome]. ( Li, HJ; Li, HZ; Yan, S; Zhang, XY, 2009)
"To evaluate the clinical efficacy and safety of dexketoprofen trometamol in the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)."5.14[Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome]. ( Jiang, MH; Liu, HL; Wu, GC, 2009)
"To evaluate the initial, long-term, and durable response rates to terazosin, placebo, or other therapies in patients with chronic prostatitis/chronic pelvic pain syndrome."5.11Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2004)
"Terazosin proved superior to placebo for patients with chronic prostatitis/chronic pelvic pain syndrome who had not received alpha-blockers previously."5.10Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2003)
"The effects of prazosin therapy were recently evaluated in ambulatory patients with essential hypertension and chronic obstructive pulmonary disease."5.06Prazosin in hypertensive patients with chronic bronchitis and asthma: a brief report. ( Chodosh, S; Pizzuto, D; Tuck, J, 1989)
"The long-term effects of prazosin in chronic congestive heart failure were studied in 10 patients (New York Heart Association class III-IV) in a double-blind cross-over study."5.06Hemodynamic effects at rest and during exercise in long-term treatment with prazosin in chronic congestive heart failure. ( Koss, A; Sivertssen, E; Westheim, A, 1986)
"Right heart catheterization was performed before and during long-term therapy with prazosin in 27 patients with severe chronic heart failure who underwent serial hemodynamic studies during 3 to 12 weeks of treatment with the drug."5.06Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1986)
"To investigate the mechanism of pharmacodynamic tolerance reported to occur during prazosin therapy of chronic congestive heart failure, we measured plasma norepinephrine, plasma epinephrine, plasma renin activity (PRA) and plasma aldosterone, as well as hemodynamics in eight patients with chronic congestive heart failure, functional class III and IV (NYHA), before and during 10 weeks of prazosin therapy."5.05Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure. ( Henry, DP; Stein, L; Weinberger, MH, 1981)
"Ten patients with severe chronic heart failure were given prazosin 5 mg and captopril 25 mg in random order on consecutive days."5.05Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects. ( Coxon, R; Sharpe, DN, 1982)
"The acute haemodynamic effects of prazosin 5 mg were investigated in 11 patients with severe chronic congestive cardiac failure."5.05Prazosin in the treatment of severe chronic congestive cardiac failure. ( Clarke, GM; Cope, GD; Hockings, BE; Taylor, RR, 1980)
"Long-term treatment of congestive heart failure with prazosin is disputed."5.05[Lack of symptomatic and long-term hemodynamic effects of prazosin in chronic heart failure. Double-blind, randomized study over one year]. ( Bussmann, WD; Kaltenbach, M; Nadj, M; Reifart, N; Schmidt-Moritz, AD, 1985)
" In cobalt-induced epilepsy in the rat activity is associated with a cortical NA denervation."4.77Chronic cobalt-induced epilepsy: noradrenaline ionophoresis and adrenoceptor binding studies in the rat cerebral cortex. ( Bregman, B; Chauvel, P; Le Saux, F; Maurin, Y; Trottier, S, 1985)
"Oral prazosin hydrochloride (2-20 mg/day) was administered to 38 patients with chronic congestive heart failure due to ischemic heart disease for 6-18 months."3.68Prazosin in chronic congestive heart failure due to ischemic heart disease. ( Antani, JA; Antani, NJ; Nanivadekar, AS, 1991)
"The purpose of the present study was to find out whether the beneficial effect of prazosin in congestive heart failure persists after 2 and 6 months of treatment and whether the clinical and haemodynamic data obtained correlate with the response to treatment."3.67[Value of early vasodilator treatment with prazosin in chronic cardiac insufficiency]. ( Aumont, MC; Cohen-Solal, A; Gourgon, R; Le Pailleur, C; Motté, G; Vacheron, A, 1987)
"Arginine vasopressin is elevated in congestive heart failure."3.67Short-term hemodynamic effects of vasopressin V1-receptor inhibition in chronic right-sided congestive heart failure. ( Hood, WB; Imai, N; Liang, CS; Sakamoto, S; Sladek, CD; Stone, CK, 1988)
"The effect of vasodilator therapy in chronic obstructive lung disease with pulmonary hypertension was evaluated in eight patients during oral prazosin therapy (2-10 mg day-1)."3.67Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale. ( Halvorsen, FJ; Jentoft, H; Vik-Mo, H; Walde, N, 1985)
"The persistence of the hemodynamic effects of prazosin was studied in 12 patients with chronic congestive heart failure."3.66Attenuation of prazosin effect on cardiac output in chronic heart failure. ( Arnold, SB; Baughman, RA; Benet, LZ; Chatterjee, K; Parmley, WW; Ports, TA; Williams, RL, 1979)
" New drugs for the treatment of severe congestive heart failure include dopamine, which has a selective nonadrenergic dilator effect on the renal vascular bed, and dobutamine, which has potent inotropic effects, lowers the left ventricular filling pressure and does not increase the heart rate or the systemic vascular resistance."3.66Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure. ( Armstrong, PW, 1979)
"The comparative haemodynamic effects of oral prazosin hydrochloride and hydralazine were evaluated in 11 patients with chronic congestive heart failure."3.66Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure. ( Arnold, S; Brundage, B; Chatterjee, K; Parmley, W; Ports, TA, 1979)
"The haemodynamic effects of oral prazosin and hydralazine were evaluated in patients with refractory heart failure and compared with those of intravenous nitroprusside in the same patients."3.66Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure. ( Conti, CR; Iacona, M; Mehta, J; Pepine, CJ, 1979)
"Twelve patients with severe chronic congestive heart failure (CHF) (NYHA class III and IV) resistant to digitalis and diuretics were treated with the postsynaptic alpha-blocking agent prazosin (PZ) (3 to 20 mg/day)."3.66Sustained effectiveness of chronic prazosin therapy in severe chronic congestive heart failure. ( Bertel, O; Bühler, FR; Burkart, F, 1981)
"The acute hemodynamic effects of oral prazosin were investigated in 7 patients with chronic refractory heart failure."3.66Acute and chronic cardiocirculatory effects of oral prazosin in chronic refractory heart failure. ( Fukaya, T; Hayashi, H; Matsui, E; Niwa, T; Oba, M; Okubo, M; Sassa, H, 1980)
"To evaluate whether long-term administration of the oral vasodilator, prazosin, in the ambulatory therapy of chronic refractory congestive heart failure (CHF) results in gradual attentuation of its marked salutary peripheral circulatory relaxing actions, 16 coronary heart failure patients receiving chronic prazosin, 16 mg daily, were assessed for the development of vasodilator tolerance for 12 months."3.66Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy. ( Awan, NA; DeMaria, AN; Lee, G; Mason, DT, 1981)
"In addition to digitalis and diuretics, 10 patients with chronic cardiac failure were treated with prazosin (15 mg/d) over a period of 6 months."3.66[Prazosin long-term treatment in severe chronic cardiac failure (author's transl)]. ( Bleifeld, W; Hanrath, P; Kuck, KH; Mathey, D; Zehnke, A, 1980)
"The long-term efficacy of the new oral vasodilator, prazosin (PZ), was evaluated in nine patients with refractory heart failure due to chronic coronary heart disease."3.65Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodyn ( Awan, NA; DeMaria, AN; Mason, DT; Maxwell, KS; Miller, RR; Neumann, A, 1977)
"Nine older men with chronic PTSD secondary to military or Holocaust trauma were prescribed the lipophilic alpha-1 adrenergic antagonist prazosin for treatment-resistant trauma-related nightmares."2.71Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. ( Bonner, LT; Hoff, DJ; Peskind, ER; Raskind, MA, 2003)
"Change in overall PTSD severity exclusive of nightmares was estimated by assigning a Clinical Global Impressions-Change scale (CGI-C) score based on chart review."2.70Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. ( Dobie, DJ; Hoff, DJ; McFall, ME; Peskind, ER; Petrie, EC; Raskind, MA; Rein, RJ; Thompson, C, 2002)
"Terazosine was effective for the treatment of CPPS."2.70Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. ( Eroğlu, M; Gül, O; Ozok, U, 2001)
"Such episodes (known as autonomic dysreflexia) are thought to result from the loss of descending baroreflex inhibition and/or plasticity within the spinal cord."1.32Tail arteries from chronically spinalized rats have potentiated responses to nerve stimulation in vitro. ( Brock, JA; McLachlan, EM; Yeoh, M, 2004)
"Prudence is indicated in patients with congestive heart failure due to coronary artery disease."1.27A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983)
"Prazosin is a post-synaptic alpha-blocker which acts on both cardiac preload and afterload."1.27[Prazosin in the treatment of chronic cardiac insufficiency]. ( Champoud, O; Cribier, A; Letac, B, 1985)
"Isosorbide dinitrate was used in 16 patients, nitroglycerin in 36, pratsiol in 24, and captopryl in 20 patients."1.27[Comparative evaluation of the effectiveness of various peripheral vasodilators in the treatment of cardiac insufficiency]. ( Ageev, FT; Evdokimova, NKh; Mareev, VIu; Mukharliamov, NM; Novikov, SV, 1985)

Research

Studies (86)

TimeframeStudies, this research(%)All Research%
pre-199062 (72.09)18.7374
1990's7 (8.14)18.2507
2000's14 (16.28)29.6817
2010's3 (3.49)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhang, XY2
Luo, SB1
Zhang, JY1
Meng, ZC1
Wang, J2
Yan, D1
Liang, K1
Xu, Z1
Yan, S1
Li, HZ1
Li, HJ1
Jiang, MH1
Wu, GC1
Liu, HL1
Wang, L1
Liang, P1
Yang, W1
Zhou, P1
Huang, XK1
Liu, JW1
Chao, WF1
Yang, H1
Wang, QT1
Raskind, MA4
Thompson, C1
Petrie, EC2
Dobie, DJ2
Rein, RJ1
Hoff, DJ2
McFall, ME1
Peskind, ER4
Li, J1
Lu, R1
Wang, JM1
Cheah, PY2
Liong, ML2
Yuen, KH2
Teh, CL2
Khor, T2
Yang, JR2
Yap, HW2
Krieger, JN2
Bonner, LT1
Yeoh, M1
McLachlan, EM1
Brock, JA1
Minervini, A1
Lapini, A1
Serni, S1
Carini, M1
Tual, L1
Morel, OE1
Favret, F1
Fouillit, M1
Guernier, C1
Buvry, A1
Germain, L1
Dhonneur, G1
Bernaudin, JF1
Richalet, JP1
Tapp, AM1
Kennedy, A1
Novikov, SV2
Mareev, VIu2
Mason, DT7
Awan, NA6
Joye, JA1
Lee, G2
DeMaria, AN3
Amsterdam, EA1
Lui, HK1
Froer, KL1
Hall, D1
Rudolph, W1
Szmydt, W1
Kaftańska, A1
Paradowski, S1
Satinsky, JD1
Netz, H1
Hagel, KJ1
Röhner, G1
Rautenburg, HW1
Shen, LH1
Ku, FS1
Liu, QS1
Guzińska, B1
Nartowicz, E1
Okamura, K1
Takamatsu, T1
Koyanagi, T1
Sharpe, DN1
Coxon, R1
Tomov, I2
Kaloianova, A2
Terzieva, L2
Nikolov, G2
Elenkova, A2
Chatterjee, K5
Parmley, WW2
Bassand, JP1
Becque, O1
Berthout, P1
Vial, Y1
Magnin, D1
Bernard, Y1
Maurat, JP1
Rutishauser, W1
Hockings, BE1
Cope, GD1
Clarke, GM1
Taylor, RR1
Ihlen, H1
Thaulow, E1
Kjekshus, J1
Forfang, K1
Rouleau, JL1
Massie, BM1
Berkowitz, RL1
Gunnar, RM1
Hayashi, H1
Sassa, H1
Oba, M1
Fukaya, T1
Okubo, M1
Niwa, T1
Matsui, E1
Stein, L1
Henry, DP1
Weinberger, MH1
Kukes, VG1
Zisel'man, SB1
Shustikova, GB1
Rumiantsev, AS1
Shagako, EV1
Bertel, O1
Burkart, F1
Bühler, FR1
Kuhn, H1
Boch, H1
Lösse, B1
Silke, B1
Taylor, SH1
Honda, T1
Hiramori, K1
Haze, K1
Saito, M1
Fuseno, H1
Fukami, K1
Umemoto, M1
Tanaka, N1
Ikeda, M1
Bussmann, WD2
Cabaniss, CD1
Kuck, KH1
Hanrath, P1
Zehnke, A1
Mathey, D1
Bleifeld, W1
Paterna, S1
Martino, S1
Ingurgio, NC1
Arrostuto, A1
Correo, S1
Licata, G1
Drabick, JJ1
Gambel, JM1
Mackey, JF1
Kontani, H1
Hayashi, K1
Lee, JZ1
Omata, S1
Tillig, B1
Perkash, I1
Constantinou, CE1
Kanter, ED1
Thompson, CE1
Hord, AH1
Denson, DD1
Stowe, B1
Haygood, RM1
Gül, O1
Eroğlu, M1
Ozok, U1
Pettinger, WA1
Massie, B1
Rubin, S1
Gelberg, H1
Brundage, BH1
Ports, TA3
Lloyd, EA1
Aronow, WS1
Danahy, DT1
Packer, M3
Meller, J2
Elkayam, U1
Lejemtel, TH1
Mathur, M1
Ribner, HS1
Frishman, WH1
Strom, J1
Sonnenblick, EH1
Arnold, SB1
Williams, RL1
Baughman, RA1
Benet, LZ1
Armstrong, PW1
Arnold, S1
Brundage, B1
Parmley, W1
Mehta, J1
Iacona, M1
Pepine, CJ1
Conti, CR1
Miller, RR2
Miller, MP1
Specht, K1
Vera, Z1
Gorlin, R1
Herman, MV1
Braunwald, E1
Maxwell, KS1
Neumann, A1
Kondratenko, TIa1
Kuzina, NV1
Zakharova, IV1
Leont'ev, AF1
Pashkevich, DD1
Seniakovich, VM1
Aleksandrov, AE1
Klochkov, SA1
Rowley, KG1
Tung, LH1
Hodsman, GP1
Howes, LG1
Jarrott, B1
Beart, PM1
Louis, WJ1
Antani, JA1
Antani, NJ1
Nanivadekar, AS1
Champoud, O1
Cribier, A1
Letac, B1
Medina, N1
Yushak, M1
Chodosh, S1
Tuck, J1
Pizzuto, D1
McMillan, M1
Chernow, B1
Roth, BL1
Le Pailleur, C1
Aumont, MC1
Cohen-Solal, A1
Gourgon, R1
Motté, G1
Vacheron, A1
Stone, CK1
Liang, CS1
Imai, N1
Sakamoto, S1
Sladek, CD1
Hood, WB1
Westheim, A1
Koss, A1
Sivertssen, E1
Bregman, B1
Le Saux, F1
Trottier, S1
Chauvel, P1
Maurin, Y1
Jalil, J1
Escobar, E1
Thumala, A1
Domenech, R1
Venegas, P1
Reifart, N1
Schmidt-Moritz, AD1
Nadj, M1
Kaltenbach, M1
Bayliss, J1
Norell, MS1
Canepa-Anson, R1
Reid, C1
Poole-Wilson, P1
Sutton, G1
Mukharliamov, NM1
Evdokimova, NKh1
Ageev, FT1
Vik-Mo, H1
Walde, N1
Jentoft, H1
Halvorsen, FJ1
Ogawa, T1
Sekiguchi, T1
Ishii, M1
Sugishita, Y1
Ito, I1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees[NCT00261729]210 participants (Anticipated)Interventional2004-07-31Completed
Prazosin for Noncombat Trauma PTSD[NCT00183430]20 participants (Actual)Interventional2003-10-31Terminated (stopped due to Insufficient Enrollment)
A Placebo-Controlled Trial of Prazosin vs. Paroxetine in Combat Stress-Related PTSD Nightmares and Sleep Disturbance[NCT00202449]59 participants (Actual)Interventional2004-07-31Terminated (stopped due to recruitment difficulties)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Recurring Distressing Dreams and Difficulty Falling and Staying Asleep Items of the CAPS

"Item B-2 recurrent distressing dreams of the event is a single item from teh Clinician Administered PTSD Scale (CAPS). The rating consists of two parts: Frequency plus Intensity. Symptom frequency rated 0 to 4. Symptom intensity rated 0 to 4. Frequency plus Intensity ratings equal the total score. The total minimum score = zero. The total maximum score = 8. A higher score is worse; a lower score is better. This outcome measure evaluates the change in score from Baseline to Week 8." (NCT00183430)
Timeframe: Baseline to Week 8

InterventionUnits on a Scale (Mean)
Prazosin-2.00
Placebo-1.09

Change in Sleep Assessed by the Pittsburgh Sleep Quality Index

Pittsburgh Sleep Quality Index is a self-report questionnaire assessing sleep quality and disturbances over a 1-month time interval. A global score is obtained by summing the seven component subscales (total score range: 0-21). A score of 5 or less indicates good sleep quality. A score of more than 5 indicates poor sleep quality. Change is measured from Baseline to Week 8. (NCT00183430)
Timeframe: Baseline to Week 8

InterventionUnits on a Scale (Mean)
Prazosin4
Placebo2.09

Clinical Global Impression of Change

The Clinical Global Impression of Change is a 7-point scale that rates global change compared to baseline (1=markedly improved, 2=moderately improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=moderately worse, 7=markedly worse). The Clinical Global Impression of Change is used to determine the impact of treatment effects on meaningful and distinct change in overall sense of well-being and functioning. This outcome measure evaluates change from Baseline to Week 8. (NCT00183430)
Timeframe: Baseline to Week 8

InterventionUnits on a Scale (Mean)
Prazosin2.33
Placebo3.27

Change in Combat Trauma-related Nightmares From the Clinician Administered PTSD Scale (CAPS) Recurrent Distressing Dreams Item at Week 12

"Item B-2 recurrent distressing dreams of the event is a single item from the Clinician Administered PTSD Scale. The rating consists of two parts: Frequency and Intensity. Symptom frequency rated 0 to 4. Symptom intensity rated 0 to 4. Frequency plus Intensity ratings equal the total score. A higher score is worse; a lower score is better. This outcome measure evaluates the change in score from Baseline to Week 12. Minimum = 0 Maximum = 8" (NCT00202449)
Timeframe: Baseline and Week 12

Interventionscale points (Mean)
Prazosin-1.29
Paroxetine-3.11
Placebo-2.67

Change in Global Trauma-related Symptom Severity and Functioning From the Clinical Global Impression of Change From Baseline to Week 12

The Clinical Global Impression of Change is a 7-point scale that rates global change compared to baseline (1=markedly improved, 2=moderately improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=moderately worse, 7=markedly worse). The CGIC is used to determine the impact of treatment effects on meaningful and distinct change in overall sense of well-being and functioning. This outcome measure evaluates change from baseline to Week 12. (NCT00202449)
Timeframe: Baseline to Week 12

Interventionscale points (Mean)
Prazosin3.14
Paroxetine2.11
Placebo2.33

Change in Sleep From the Pittsburgh Sleep Quality Index From Baseline to Week 12

Pittsburgh Sleep Quality Index is a self-report questionnaire assessing sleep quality and disturbances over a 1-month time interval. A global score is obtained by summing the seven component subscales (total score range: 0-21). A score of 5 or less indicates good sleep quality. A score of more than 5 indicates poor sleep quality. Change is measured from Baseline to Week 12. (NCT00202449)
Timeframe: Baseline to Week 12

Interventionscale points (Mean)
Prazosin-2.33
Paroxetine-6.44
Placebo-3.33

Reviews

9 reviews available for prazosin and Chronic Disease

ArticleYear
[Adrenergic alpha-receptor blockaders and direct arteriolar vasodilators in treatment of chronic cardiac insufficiency].
    Terapevticheskii arkhiv, 1983, Volume: 55, Issue:5

    Topics: Adrenergic alpha-Antagonists; Arterioles; Cardiac Output, Low; Chronic Disease; Hemodynamics; Humans

1983
Vasodilator therapy for chronic heart failure.
    Annual review of pharmacology and toxicology, 1980, Volume: 20

    Topics: Captopril; Chronic Disease; Heart Failure; Hemodynamics; Humans; Hydralazine; Nitrates; Nitroglyceri

1980
Anti-hypertensive drugs in the pregnant patient.
    Obstetrical & gynecological survey, 1980, Volume: 35, Issue:4

    Topics: Antihypertensive Agents; Chronic Disease; Clonidine; Diazoxide; Diuretics; Female; Fetus; Furosemide

1980
The role of vasodilating agents in the treatment of chronic heart failure.
    Angiology, 1980, Volume: 31, Issue:8

    Topics: Cardiac Output; Chronic Disease; Dobutamine; Heart Failure; Humans; Muscle Contraction; Nitroprussid

1980
Recent advances in the treatment of hypertension.
    Archives of internal medicine, 1977, Volume: 137, Issue:5

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Chronic Disease; Clonidine; Diazoxide; Drug Th

1977
Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure.
    The American journal of medicine, 1978, Volume: 65, Issue:1

    Topics: Aorta; Cardiac Output; Chronic Disease; Heart; Heart Failure; Heart Ventricles; Hemodynamics; Humans

1978
The use of vasodilator agents in the treatment of heart failure.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1979, Nov-10, Volume: 56, Issue:20

    Topics: Cardiac Output; Cardiomegaly; Catheterization; Chronic Disease; Coronary Vessels; Dose-Response Rela

1979
Oral vasodilator therapy for chronic heart failure: a plea for caution.
    The American journal of cardiology, 1978, Volume: 42, Issue:4

    Topics: Cardiac Output; Chronic Disease; Forecasting; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin

1978
Chronic cobalt-induced epilepsy: noradrenaline ionophoresis and adrenoceptor binding studies in the rat cerebral cortex.
    Journal of neural transmission, 1985, Volume: 63, Issue:2

    Topics: Animals; Cerebral Cortex; Chronic Disease; Clonidine; Cobalt; Dihydroalprenolol; Epilepsy; Iontophor

1985

Trials

26 trials available for prazosin and Chronic Disease

ArticleYear
[Triple acupuncture at the Qugu acupoint as an adjunctive therapy for type-Ⅲ chronic prostatitis: Analysis of short- and long-term clinical effects].
    Zhonghua nan ke xue = National journal of andrology, 2017, Volume: 23, Issue:5

    Topics: Acupuncture Points; Acupuncture Therapy; Anti-Bacterial Agents; Chronic Disease; Chronic Pain; Combi

2017
A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome.
    International urology and nephrology, 2016, Volume: 48, Issue:1

    Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Chronic Disease; Drug Therapy, Combination; Huma

2016
[Retrospective analysis of the combined therapy of terazosin with chlormezanone for chronic prostatitis/chronic pelvic pain syndrome].
    Zhonghua nan ke xue = National journal of andrology, 2009, Volume: 15, Issue:8

    Topics: Adult; Chlormezanone; Chronic Disease; Drug Therapy, Combination; Humans; Male; Middle Aged; Pain Me

2009
[Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome].
    Zhonghua nan ke xue = National journal of andrology, 2009, Volume: 15, Issue:9

    Topics: Adult; Chronic Disease; Humans; Indomethacin; Ketoprofen; Male; Pelvic Pain; Prazosin; Prostatitis;

2009
[Efficacy of compound Xuanju capsule in the treatment of chronic prostatitis with erectile dysfunction].
    Zhonghua nan ke xue = National journal of andrology, 2012, Volume: 18, Issue:10

    Topics: Adult; Capsules; Chronic Disease; Drugs, Chinese Herbal; Erectile Dysfunction; Humans; Levofloxacin;

2012
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:7

    Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged;

2002
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:7

    Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged;

2002
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:7

    Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged;

2002
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:7

    Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged;

2002
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:7

    Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged;

2002
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:7

    Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged;

2002
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:7

    Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged;

2002
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:7

    Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged;

2002
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:7

    Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged;

2002
[Treatment of external RF hyperthermia combining with alpha 1-adrenergic receptor blocker for patients with prostatodynia and chronic non-bacterial prostatitis].
    Zhonghua nan ke xue = National journal of andrology, 2002, Volume: 8, Issue:1

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Chronic Disease; Combi

2002
Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial.
    The Journal of urology, 2003, Volume: 169, Issue:2

    Topics: Adrenergic alpha-Antagonists; Adult; Chronic Disease; Humans; Male; Middle Aged; Pelvic Pain; Prazos

2003
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
    Journal of geriatric psychiatry and neurology, 2003, Volume: 16, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug

2003
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
    Journal of geriatric psychiatry and neurology, 2003, Volume: 16, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug

2003
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
    Journal of geriatric psychiatry and neurology, 2003, Volume: 16, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug

2003
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
    Journal of geriatric psychiatry and neurology, 2003, Volume: 16, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug

2003
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
    Journal of geriatric psychiatry and neurology, 2003, Volume: 16, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug

2003
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
    Journal of geriatric psychiatry and neurology, 2003, Volume: 16, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug

2003
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
    Journal of geriatric psychiatry and neurology, 2003, Volume: 16, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug

2003
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
    Journal of geriatric psychiatry and neurology, 2003, Volume: 16, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug

2003
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
    Journal of geriatric psychiatry and neurology, 2003, Volume: 16, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug

2003
Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome.
    Urology, 2004, Volume: 64, Issue:5

    Topics: Adrenergic alpha-Antagonists; Adult; Chronic Disease; Double-Blind Method; Follow-Up Studies; Humans

2004
[Clinical and polycardiographic evaluation of prazosin in the treatment of chronic congestive heart failure].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1984, Nov-12, Volume: 39, Issue:46

    Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Heart Failure; Heart Function Tests;

1984
Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects.
    Australian and New Zealand journal of medicine, 1982, Volume: 12, Issue:5

    Topics: Aged; Aldosterone; Blood Pressure; Captopril; Chronic Disease; Clinical Trials as Topic; Coronary Di

1982
[Treatment of chronic congestive failure with vasodilators (acute trial with prazosin and erythrityl tetranitrate)].
    Vutreshni bolesti, 1982, Volume: 21, Issue:6

    Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Clinical Trials as Topic; Erythrityl T

1982
Prazosin in the treatment of severe chronic congestive cardiac failure.
    Australian and New Zealand journal of medicine, 1980, Volume: 10, Issue:4

    Topics: Adult; Aged; Chronic Disease; Echocardiography; Follow-Up Studies; Heart Failure; Hemodynamics; Huma

1980
Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure.
    The American journal of medicine, 1981, Volume: 70, Issue:4

    Topics: Aged; Chronic Disease; Clinical Trials as Topic; Drug Tolerance; Epinephrine; Female; Heart Failure;

1981
[Vasodilator treatment of chronic heart failure: a chronic double-blind trial with prazosin and erythrityl tetranitrate].
    Vutreshni bolesti, 1981, Volume: 20, Issue:6

    Topics: Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Erythrityl Tetranitrate; Female; Hea

1981
[The effects of terazosin hydrochloride and buflomedil in patients with hemicrania without aura].
    La Clinica terapeutica, 1994, Volume: 144, Issue:4

    Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Chronic Disease; Drug Therapy, Combination; Female;

1994
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index.
    International urology and nephrology, 2001, Volume: 32, Issue:3

    Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Chronic Disease; Humans; Male; Middle Aged; Prazosi

2001
Efficacy of trimazosin and prazosin therapy on cardiac and exercise performance in outpatients with chronic congestive heart failure.
    The American journal of medicine, 1978, Volume: 65, Issue:1

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Dou

1978
[Adrenergic receptors in the liver parenchyma in children with chronic hepatitis].
    Biulleten' eksperimental'noi biologii i meditsiny, 1992, Volume: 113, Issue:2

    Topics: Adolescent; Binding Sites; Child; Child, Preschool; Chronic Disease; Dihydroalprenolol; Hepatitis; H

1992
Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure.
    Journal of the American College of Cardiology, 1986, Volume: 7, Issue:3

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Drug Tolerance

1986
Prazosin in hypertensive patients with chronic bronchitis and asthma: a brief report.
    The American journal of medicine, 1989, Jan-23, Volume: 86, Issue:1B

    Topics: Asthma; Blood Pressure; Bronchitis; Chronic Disease; Forced Expiratory Volume; Humans; Hypertension;

1989
Hemodynamic effects at rest and during exercise in long-term treatment with prazosin in chronic congestive heart failure.
    Acta medica Scandinavica, 1986, Volume: 219, Issue:5

    Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Heart Failure;

1986
[Lack of symptomatic and long-term hemodynamic effects of prazosin in chronic heart failure. Double-blind, randomized study over one year].
    Zeitschrift fur Kardiologie, 1985, Volume: 74, Issue:4

    Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Heart Failure; Heart Va

1985
Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin.
    British medical journal (Clinical research ed.), 1985, Jun-22, Volume: 290, Issue:6485

    Topics: Aged; Captopril; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; F

1985

Other Studies

51 other studies available for prazosin and Chronic Disease

ArticleYear
Tail arteries from chronically spinalized rats have potentiated responses to nerve stimulation in vitro.
    The Journal of physiology, 2004, Apr-15, Volume: 556, Issue:Pt 2

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Arteries; Autonomic Dysreflexia; C

2004
Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome.
    Urology, 2005, Volume: 66, Issue:1

    Topics: Chronic Disease; Humans; Male; Pelvic Pain; Prazosin; Prostatitis; Syndrome; Time Factors

2005
Carvedilol inhibits right ventricular hypertrophy induced by chronic hypobaric hypoxia.
    Pflugers Archiv : European journal of physiology, 2006, Volume: 452, Issue:4

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Hypertrop

2006
Beneficial effects of prazosin for visual hallucinations associated with chronic cocaine abuse.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:11

    Topics: Adrenergic alpha-Antagonists; Chronic Disease; Cocaine-Related Disorders; Crack Cocaine; Hallucinati

2006
Treatment of acute and chronic congestive heart failure by vasodilator-afterload reduction.
    Archives of internal medicine, 1980, Volume: 140, Issue:12

    Topics: Acute Disease; Antihypertensive Agents; Blood Pressure; Cardiac Output; Chronic Disease; Diastole; H

1980
Effects of alpha-receptor blockade with prazosin in advanced chronic congestive heart failure.
    Herz, 1983, Volume: 8, Issue:2

    Topics: Chronic Disease; Heart Failure; Hemodynamics; Humans; Prazosin; Quinazolines; Receptors, Adrenergic,

1983
[Captopril in chronic congestive heart failure--dose-effect behavior and comparison with prazosin].
    Herz, 1983, Volume: 8, Issue:2

    Topics: Adult; Aged; Captopril; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Fema

1983
Chronic heart failure in the elderly: vasodilator therapy.
    Angiology, 1983, Volume: 34, Issue:8

    Topics: Aged; Blood Pressure; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Humans; Hydralazine

1983
Prazosin for refractory cardiac failure in children.
    Pediatric cardiology, 1984, Volume: 5, Issue:4

    Topics: Adolescent; Child; Child, Preschool; Chronic Disease; Heart Failure; Humans; Infant; Male; Prazosin;

1984
[Hemodynamic effects and clinical observations on prazosin in treating chronic refractory congestive heart failure].
    Zhonghua xin xue guan bing za zhi, 1984, Volume: 12, Issue:4

    Topics: Adult; Aged; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazos

1984
[Effect of vasodilator treatment of chronic circulatory insufficiency on various polycardiographic parameters].
    Kardiologia polska, 1983, Volume: 26, Issue:7

    Topics: Chronic Disease; Drug Therapy, Combination; Female; Heart; Heart Failure; Heart Function Tests; Huma

1983
[Management of chronic spinal cord injury patients with prazosin].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1983, Volume: 74, Issue:9

    Topics: Adult; Chronic Disease; Female; Humans; Male; Middle Aged; Prazosin; Quinazolines; Spinal Cord Injur

1983
[Hemodynamic effects of prazosin in chronic congestive heart failure].
    Archives des maladies du coeur et des vaisseaux, 1980, Volume: 73, Issue:6

    Topics: Aged; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazosin; Qui

1980
A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure.
    European heart journal, 1983, Volume: 4 Suppl A

    Topics: Chronic Disease; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Humans; Hydralazine; N

1983
Loss of prazosin effect in severe chronic CHF.
    Acta medica Scandinavica. Supplementum, 1981, Volume: 652

    Topics: Adult; Aged; Bed Rest; Chronic Disease; Drug Tolerance; Echocardiography; Female; Heart Failure; Hem

1981
Hydralazine in chronic CHF.
    Acta medica Scandinavica. Supplementum, 1981, Volume: 652

    Topics: Administration, Oral; Aortic Valve Insufficiency; Cardiac Output; Chronic Disease; Drug Therapy, Com

1981
Acute and chronic cardiocirculatory effects of oral prazosin in chronic refractory heart failure.
    Japanese heart journal, 1980, Volume: 21, Issue:6

    Topics: Administration, Oral; Aged; Blood Pressure; Chronic Disease; Female; Heart Failure; Heart Rate; Hemo

1980
[Use of the new hypotensive agent Minipress (prazosin hydrochloride].
    Kardiologiia, 1982, Volume: 22, Issue:3

    Topics: Adult; Antihypertensive Agents; Chronic Disease; Drug Evaluation; Female; Hemodynamics; Humans; Hype

1982
Sustained effectiveness of chronic prazosin therapy in severe chronic congestive heart failure.
    American heart journal, 1981, Volume: 101, Issue:5

    Topics: Aged; Chronic Disease; Dizziness; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pr

1981
Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy.
    American heart journal, 1981, Volume: 101, Issue:5

    Topics: Administration, Oral; Ambulatory Care; Chronic Disease; Drug Tolerance; Forearm; Heart Failure; Hemo

1981
Oral vasodilator therapy with prazosin in severe congestive heart failure.
    American heart journal, 1981, Volume: 101, Issue:5

    Topics: Acute Disease; Administration, Oral; Ambulatory Care; Chronic Disease; Heart Failure; Hemodynamics;

1981
[Chronic administration of prazosin in patients with congestive cardiomyopathy (author's transl)].
    Zeitschrift fur Kardiologie, 1981, Volume: 70, Issue:7

    Topics: Adult; Chronic Disease; Echocardiography; Female; Heart Failure; Hemodynamics; Humans; Male; Middle

1981
Pharmacokinetic and haemodynamic studies with prazosin in chronic heart failure.
    Irish journal of medical science, 1981, Volume: 150, Issue:8

    Topics: Aged; Blood Pressure; Chronic Disease; Coronary Disease; Electrocardiography; Exercise Test; Female;

1981
[The effects of prazosin in patients with chronic refractory heart failure-acute hemodynamic effects of oral prazosin and long-term therapy (author's transl)].
    Kokyu to junkan. Respiration & circulation, 1981, Volume: 29, Issue:5

    Topics: Administration, Oral; Adult; Aged; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Mal

1981
[Acute and chronic treatment of chronic cardiac insufficiency with nitrates or prazosin respectively].
    Therapeutische Umschau. Revue therapeutique, 1981, Volume: 38 Suppl

    Topics: Acute Disease; Chronic Disease; Heart Failure; Humans; Nitrates; Prazosin; Quinazolines

1981
Vasodilator therapy of chronic congestive heart failure.
    Journal of the Medical Association of Georgia, 1980, Volume: 69, Issue:2

    Topics: Ambulatory Care; Chronic Disease; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin; Quinazolin

1980
[Prazosin long-term treatment in severe chronic cardiac failure (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1980, Oct-03, Volume: 105, Issue:40

    Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Digitalis Glycosides; Diuretics; Drug

1980
Prostatodynia in United Nations peacekeeping forces in Haiti.
    Military medicine, 1997, Volume: 162, Issue:6

    Topics: Abscess; Adrenergic alpha-Antagonists; Adult; Age Factors; Anti-Bacterial Agents; Chronic Disease; C

1997
Urinary bladder response to hypogastric nerve stimulation after bilateral resection of the pelvic nerve or spinal cord injury in rats.
    International journal of urology : official journal of the Japanese Urological Association, 1997, Volume: 4, Issue:4

    Topics: Animals; Atropine; Chronic Disease; Electric Stimulation; Hexamethonium; Hypogastric Plexus; Nicotin

1997
Chronology and urodynamic characterization of micturition in neurohormonally induced experimental prostate growth in the rat.
    Neurourology and urodynamics, 1998, Volume: 17, Issue:1

    Topics: Adrenergic alpha-Antagonists; Animals; Chronic Disease; Dihydrotestosterone; Disease Models, Animal;

1998
alpha-1 and alpha-2 Adrenergic antagonists relieve thermal hyperalgesia in experimental mononeuropathy from chronic constriction injury.
    Anesthesia and analgesia, 2001, Volume: 92, Issue:6

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-A

2001
Long-term outpatient vasodilator therapy of congestive heart failure. Consideration of agents at rest and during exercise.
    The American journal of medicine, 1978, Volume: 65, Issue:1

    Topics: Chronic Disease; Drug Therapy, Combination; Heart Failure; Heart Ventricles; Hemodynamics; Humans; H

1978
Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure.
    The American journal of cardiology, 1979, Volume: 44, Issue:3

    Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Dose-Response Re

1979
Attenuation of prazosin effect on cardiac output in chronic heart failure.
    Annals of internal medicine, 1979, Volume: 91, Issue:3

    Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Drug Administration Schedule; Female;

1979
Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure.
    Canadian Medical Association journal, 1979, Oct-06, Volume: 121, Issue:7

    Topics: Chronic Disease; Dobutamine; Dopamine; Heart; Heart Failure; Hemodynamics; Humans; Hydralazine; Moni

1979
Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure.
    British heart journal, 1979, Volume: 42, Issue:6

    Topics: Adult; Aged; Cardiac Output; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Hydralazi

1979
Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure.
    British heart journal, 1979, Volume: 42, Issue:6

    Topics: Adult; Aged; Chronic Disease; Ferricyanides; Heart Failure; Hemodynamics; Humans; Hydralazine; Male;

1979
Clinical pharmacology and therapeutic application of prazosin in acute and chronic refractory congestive heart failure. Balanced systemic venous and arterial dilation improving pulmonary congestion and cardiac output.
    The American journal of medicine, 1978, Volume: 65, Issue:1

    Topics: Acute Disease; Arteries; Cardiac Output; Chronic Disease; Electrocardiography; Forearm; Heart Failur

1978
Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure.
    Circulation, 1979, Volume: 59, Issue:3

    Topics: Aged; Chronic Disease; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Humans; Middle

1979
Vasodilator therapy--a physiologic approach to the treatment of heart failure.
    The New England journal of medicine, 1977, Aug-11, Volume: 297, Issue:6

    Topics: Administration, Oral; Advertising; Chronic Disease; Heart Failure; Hemodynamics; Humans; Prazosin; Q

1977
Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodyn
    Circulation, 1977, Volume: 56, Issue:3

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Blood Pressure; Cardiac Output; Chronic Disease;

1977
Altered alpha 1-adrenoceptor-mediated responses in atria of rats with chronic left ventricular infarction.
    Journal of cardiovascular pharmacology, 1991, Volume: 17, Issue:3

    Topics: Animals; Chronic Disease; Female; Heart; Heart Rate; Inositol Phosphates; Male; Myocardial Contracti

1991
Prazosin in chronic congestive heart failure due to ischemic heart disease.
    Clinical cardiology, 1991, Volume: 14, Issue:6

    Topics: Aged; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Female; Follow-Up

1991
[Prazosin in the treatment of chronic cardiac insufficiency].
    Annales de medecine interne, 1985, Volume: 136, Issue:3

    Topics: Adrenergic alpha-Antagonists; Arterioles; Cardiac Output; Chronic Disease; Heart Failure; Humans; Mi

1985
Hepatic alpha 1-adrenergic receptor alteration in a rat model of chronic sepsis.
    Circulatory shock, 1986, Volume: 19, Issue:2

    Topics: Animals; Bacterial Infections; Chronic Disease; Dihydroergotoxine; Disease Models, Animal; Glucose;

1986
[Value of early vasodilator treatment with prazosin in chronic cardiac insufficiency].
    Archives des maladies du coeur et des vaisseaux, 1987, Volume: 80, Issue:11

    Topics: Adult; Aged; Chronic Disease; Electrocardiography; Female; Heart Failure; Hemodynamics; Humans; Male

1987
Short-term hemodynamic effects of vasopressin V1-receptor inhibition in chronic right-sided congestive heart failure.
    Circulation, 1988, Volume: 78, Issue:5 Pt 1

    Topics: Animals; Arginine Vasopressin; Cardiac Output; Chronic Disease; Dogs; Epinephrine; Heart Failure; He

1988
[Vasodilator agents in chronic asymptomatic aortic insufficiency: echocardiographic study].
    Revista medica de Chile, 1985, Volume: 113, Issue:8

    Topics: Adult; Aged; Aortic Valve Insufficiency; Captopril; Chronic Disease; Echocardiography; Female; Hemod

1985
[Comparative evaluation of the effectiveness of various peripheral vasodilators in the treatment of cardiac insufficiency].
    Terapevticheskii arkhiv, 1985, Volume: 57, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Captopril; Chronic Disease; Female; Heart Failure; Hemodyna

1985
Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale.
    European heart journal, 1985, Volume: 6, Issue:12

    Topics: Administration, Oral; Aged; Carbon Dioxide; Chronic Disease; Female; Hemodynamics; Humans; Hypertens

1985
[Correlations between resting hemodynamics and exercise tolerance before and after prazosin therapy in patients with chronic congestive heart failure].
    Kokyu to junkan. Respiration & circulation, 1985, Volume: 33, Issue:2

    Topics: Adult; Aged; Chronic Disease; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Male; Midd

1985